
Aclipse Therapeutics receives a therapeutic development award of $1.475 million
Aclipse Therapeutics and its subsidiary Aclipse One Inc (“Aclipse” or “the Company”), an innovative biopharmaceutical company, today announced that the Company has received a therapeutic